CN108888561B

CN108888561B - Whitening composition and cosmetic prepared from same

Info

Publication number: CN108888561B
Application number: CN201810966500.9A
Authority: CN
Inventors: 敢小双
Original assignee: Infinitus China Co Ltd
Current assignee: Infinitus China Co Ltd
Priority date: 2018-08-23
Filing date: 2018-08-23
Publication date: 2021-06-11
Anticipated expiration: 2038-08-23
Also published as: CN108888561A

Abstract

The invention relates to the technical field of cosmetics, in particular to a whitening composition and a whitening cosmetic prepared from the same. The composition has the effects of improving skin color and reducing the content of melanin in the skin. Compared with the single use of each component or other comparative examples, the composition provided by the invention has remarkable improvement on the whitening effect. Experiments show that compared with the cosmetic prepared by the composition before being used, the content of melanin in the spot part is reduced by 8.08 percent after 28 days, while the content of melanin in the spot-free part is reduced by 8.16 percent, and the skin color is obviously improved.

Description

Whitening composition and cosmetic prepared from same

Technical Field

The invention relates to the technical field of cosmetics, in particular to a whitening composition and a whitening cosmetic prepared from the same.

Background

China is always beautiful in white in the ancient times, and the popular saying that the white skin covers the ugly, and the white skin is the biotical pursuit of numerous women. In recent years, as the standard of living has been improved, fair skin has become an increasingly sought-after target.

The dark pigment that is deposited on the skin is almost exclusively melanin, which is produced in melanosomes within melanocytes between the epidermis and the dermis, and the produced melanin diffuses toward adjacent cells by osmosis. The color of human skin is not dependent on the number of melanocytes, but on the number, size, distribution and degree of melanogenesis. The reasons for the generation of skin melanin mainly include genetic factors, ultraviolet rays, waste gases, active oxygen and other environmental factors; imbalance of in vivo oxidation and antioxidation balance; endocrine dyscrasia; micro-ecological imbalance; metabolic disorders; abnormal trace element content in body, etc.

The whitening agent has the function of whitening skin by inhibiting tyrosinase activity or blocking the oxidation pathway of tyrosine to generate melanin, thereby reducing the generation of melanin. The skin whitening agent is a substance which acts on the production and metabolism processes of skin melanin, inhibits the production of the melanin and meets the specification. Mercuric chloride and mercuric iodide interfere with the normal enzymatic conversion of the amino acid melanin in the skin. Therefore, many whitening cosmetics contain toxic heavy metal mercury, and even some cosmetics contain arsenic. These substances all have extremely high toxicity. Lead, arsenic and mercury in the cosmetics exceed the standard, so that the cosmetics are harmful to human health, especially inhibit the formation of germ cells, and influence the fertility of young people.

In addition, many whitening products which take Chinese herbal medicines as main whitening components exist in the market at present, and the whitening components mainly comprise: arbutin, hydroquinone, vitamin C, kojic acid, azelaic acid, cell growth factor, etc. However, these products are effective only on certain stains, such as arbutin, which is effective only on chloasma and not on freckles. Or skin irritation and damage, such as general poisoning caused by hydroquinone-containing cosmetics, and contact dermatitis caused by kojic acid in large amount. Therefore, the search for safe and effective whitening products is still a hot point of research.

Disclosure of Invention

In view of the above, the technical problem to be solved by the present invention is to provide a whitening composition and a whitening cosmetic prepared from the same. The whitening composition can effectively reduce melanin content, improve skin glossiness and chromaticity, can improve moisture content of skin cuticle, and has good safety.

The whitening composition provided by the invention comprises the following components in parts by mass:

in the embodiment of the invention, the whitening composition comprises the following components in parts by mass:

in some embodiments, the whitening composition consists of the following components in parts by mass:

the extract composition consists of the following components: mushroom extract, safflower extract, centella asiatica extract, polygonum cuspidatum root extract, scutellaria baicalensis root extract, tea extract, chamomile flower extract, rosemary leaf extract, glycyrrhiza glabra root extract, artemisia capillaris flower extract, mulberry root extract and jujube fruit extract.

In the extract composition, the mass ratio of each component is as follows: mushroom extract, safflower extract, centella asiatica extract, polygonum cuspidatum root extract, scutellaria baicalensis root extract, tea leaf extract, glycyrrhiza glabra root extract, chamomile flower extract, rosemary leaf extract, artemisia capillaris flower extract, mulberry root extract and jujube fruit extract (0.5-1.5): (0.001-0.003): (0.05-0.3): (0.05-0.3): (0.05-0.3): (0.05-0.2): (0.1-1): (0.1-0.3): (0.1-0.3): (0.03-0.2): (0.02-0.3): (0.05-0.5).

In the extract composition, the mass ratio of each component is as follows: mushroom extract, safflower extract, centella asiatica extract, polygonum cuspidatum root extract, scutellaria baicalensis root extract, tea extract, glycyrrhiza glabra root extract, chamomile extract, rosemary leaf extract, artemisia capillaris flower extract, mulberry root extract and jujube fruit extract, wherein the ratio of the mushroom extract to the safflower extract to the centella asiatica extract to the scutellaria baicalensis root extract to the tea extract is 0.5: 0.001: 0.05: 0.05: 0.05: 0.05: 0.6: 0.1: 0.1: 0.03: 0.02: 0.05.

In the extract composition, the mass ratio of each component is as follows: mushroom extract, safflower extract, centella asiatica extract, polygonum cuspidatum root extract, scutellaria baicalensis root extract, tea extract, glycyrrhiza glabra root extract, chamomile extract, rosemary leaf extract, artemisia capillaris flower extract, mulberry root extract and jujube fruit extract, wherein the ratio of the mushroom extract to the safflower extract to the asiatic pennywort herb extract to the jujube fruit extract is 1: 0.002: 0.2: 0.2: 0.2: 0.1: 0.8: 0.1: 0.1: 0.2: 0.2: 0.1.

in the extract composition, the mass ratio of each component is as follows: mushroom extract, safflower extract, centella asiatica extract, polygonum cuspidatum root extract, scutellaria baicalensis root extract, tea extract, glycyrrhiza glabra root extract, chamomile extract, rosemary leaf extract, artemisia capillaris flower extract, mulberry root extract and jujube fruit extract, wherein the ratio of the mushroom extract to the safflower extract to the centella asiatica extract to the scutellaria baicalensis root extract to the tea extract is 1.5: 0.003: 0.3: 0.3: 0.3: 0.2: 1: 0.3: 0.3: 0.2: 0.3: 0.5.

the composition formed by compounding the components such as butanediol, ascorbyl glucoside, the extract composition, nicotinamide and the like can obviously reduce the melanin content in the skin and improve the skin color. The effect is significantly improved compared with the use of each component alone or the use of the traditional whitening composition. The composition has the beneficial effects that under a proper proportion, the components are compounded to generate a synergistic effect, so that the whitening effect is improved. In the extract composition, all components are closely matched, and one is not necessary. Moreover, experiments show that the composition provided by the invention can also improve the moisture content of the stratum corneum of the skin and has good safety. The detection shows that the skin melanin content of a subject is obviously reduced after the cosmetic prepared by the composition provided by the invention is used, and the skin chromaticity L value and the ITA DEG value have obvious rising trends (P <0.001), b value and a value have certain descending trends; and after the test product is used, the visual scores of the color and the size of the skin color spots of the subjects have obvious descending trend (P <0.05), and the scores of the skin color improvement degree have obvious ascending trend (P <0.05), which shows that the cosmetics prepared by the composition provided by the invention can have good effects of lightening the color spots and improving the skin color.

The invention provides an application of a whitening composition in preparation of cosmetics.

The invention also provides a cosmetic, and the whitening composition is prepared by the method.

The cosmetic provided by the invention contains 9.75-26.09% of the whitening composition by mass.

The cosmetic provided by the invention also comprises: water, thickening agent, pH regulator, solubilizer, preservative, buffering agent, chelating agent and essence.

In the invention, the thickening agent is xanthan gum and carbomer U-20;

the pH regulator is arginine;

the solubilizer is PEG-60 hydrogenated castor oil;

the preservative is methyl paraben;

the buffer is sodium citrate and citric acid;

the chelating agent is disodium EDTA.

In the embodiment of the invention, the essence consists of a orchid essence and an aloe essence, and the mass ratio of the orchid essence to the aloe essence is 3-6.

In some embodiments, the cosmetic provided by the invention comprises the following components in percentage by mass:

the cosmetic provided by the invention is a facial mask.

The above components are present in facial mask solution of facial mask, and the cosmetic also comprises facial mask matrix.

In the invention, the mask substrate is non-woven fabric.

The composition is prepared by compounding butanediol, ascorbyl glucoside, hyaluronic acid, nicotinamide and the like, and has the effects of improving skin color and reducing the content of skin melanin. Compared with the single use of each component or other comparative examples, the composition provided by the invention has remarkable improvement on the whitening effect. Experiments show that compared with the cosmetic prepared by the composition before the use, the content of melanin in a spot part is reduced by 8.08 percent after 28 days, while the content of melanin in a spot-free part is reduced by 8.16 percent, and the skin color is obviously improved.

Detailed Description

The invention provides a whitening composition and a whitening cosmetic prepared from the same. The skilled person can use the contents to modify the process parameters appropriately. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.

The test materials adopted by the invention are all common commercial products and can be purchased in the market.

In the extract composition, the main component of the mushroom extract is polysaccharide; the main component of the safflower extract is safflower flavone; the centella asiatica extract contains asiaticoside as main component; the rhizoma Polygoni Cuspidati extract mainly contains resveratrol and emodin; the main component of radix Scutellariae extract is baicalin; the main component of the tea extract is tea polyphenol; flos Chrysanthemi extract contains flos Chrysanthemi flavone as main ingredient; the main component of the rosemary leaf extract is rosmarinic acid; the main components of Glycyrrhiza glabra root extract are glabridin (Glabrene) and glabridin; the main components of the artemisia capillaris flower extract are Cas No: 223747-93-1; the main components of the mulberry root extract are flavone and polysaccharide; the fructus Jujubae extract mainly contains fructus Jujubae saponins I, II, III, and semen Ziziphi Spinosae saponin B.

The invention is further illustrated by the following examples:

examples 1 to 3

The mass fractions of the components in the formula are shown in table 1:

TABLE 1 examples 1 to 3 formulations

Mixing the above components, stirring, and homogenizing to obtain facial mask liquid.

And subpackaging the mask liquid, mixing with a mask matrix, and packaging to obtain the mask.

Comparative examples 1 to 2

The mass fractions of the components in the formula are shown in table 2:

table 2 comparative examples 1-2 formulations

Evaluation of efficacy

1 subject screening criteria

1.1 inclusion criteria

1.1.1. Healthy Chinese women, the age of which is between 20 and 45 years old;

1.1.2. no serious chronic wasting disease (asthma, diabetes, etc.);

1.1.3. no skin injury, inflammation, eczema, etc.;

1.1.4. double-sided cheek skin is dry and dull (dull);

1.1.5. those with significant color spots on the face;

1.1.6. subjects did not participate in other clinical trials and were willing to engage in sun protection measures during the trial;

1.1.7. subjects were able to follow the trial and sign informed consent.

1.2 exclusion criteria

1. Women who are currently in pregnancy, lactation or plan to become pregnant during the next two months;

2. the tested part has dermatitis, scar or serious folliculitis and other diseases, and may affect the test result;

3. there was anti-sensitization therapy given and the last injection was within the past 8 days or will be given such treatment during the study;

4. hormone medicine is taken orally within a month or an antihistamine immune preparation is taken in a week;

5. in the last year, patients who have undergone medical beauty care such as laser beauty treatment and electric wave skin-drawing or plastic cosmetic surgery;

6. one month before the start of the study, the subjects started using the cosmetics having the whitening effect;

7. in the past two weeks, the cosmetic used on the tested part is changed or the skin care habit is changed;

8. cosmetic or pharmaceutical application to the skin at the test site on the day of inclusion;

9. cannot return the visitor on time, or is unwilling to sign an informed consent.

1.3 Exit Standard

During the test, the subject has adverse reaction, no accident or violation of the study scheme (such as using other cosmetics or drugs which have an influence on the study result) and other special reasons, and the evaluation and confirmation of the research responsible person can require the subject to quit if the subject is no longer suitable for continuing the test.

2 subjects of the disease

Through the screening, a total of 150 female subjects are selected and randomly divided into 5 groups, namely an experimental group and a control group, wherein the facial masks of the examples 1 to 3 are sequentially and respectively given to the experimental groups 1 to 3; control groups 1 to 2 were sequentially and respectively given the masks of comparative examples 1 to 2

3 test materials

3.1 test products

The whitening effect of the masks of examples 1 to 3 was evaluated by human trial for 28 days.

The face wash, moisturizing cream or sunscreen cream used for normal skin care of the subject was the same.

3.2 product application method and frequency

Test groups:

morning face cleaning → moisturizing milk → sunscreen (for daytime only)

At night, cleansing → face pack of examples 1 to 3 → moisturizing cream

Control group:

morning face cleaning → moisturizing milk → sunscreen (for daytime only)

At night, cleansing → face mask of comparative examples 1 to 2 → moisturizing cream

(Subjects used themselves at home, applied to the face once a day)

3.3 environmental conditions

The temperature is 22 +/-2 ℃, and the relative humidity is 55% +/-5%

3.4 test methods and results

TABLE 3 evaluation method number

Data analysis was performed using SPSS21.0 statistical software. The baseline (D0) and revisit values (D3, D7, D14, D21, and D28) for each parameter were analyzed for differences using repeated measures analysis of variance and generalized estimation routines. Statistically significant differences are marked with p <0.05, p <0.01, p < 0.001.

3.4.1 evaluation of safety and adverse reactions

Adverse reaction observations and assessments were performed seven times in total during the course of the experiment, revisits at D0, D3, D7, D14, D21 and D28, respectively. The test subjects were asked by a professional dermatologist whether the test products were dry, greasy, desquamating, red, stinging, etc. on the face and observed to record whether the face had rash, redness and desquamation. Scoring was then performed according to the scoring criteria of table 1, scoring was entered into the case report table, and relevance assessments were performed according to the criteria listed in table 4.

TABLE 4 scoring criteria for adverse reactions

TABLE 5 evaluation scores for test products

After 28 days of testing, no adverse reaction occurs to the test subject during the test period, which indicates that the mask prepared by the embodiment of the invention has higher safety.

3.4.2 analysis of the water content of the stratum corneum

The moisture content of the stratum corneum of the skin is measured by a Corneometer; the larger the value of the water-retaining agent is, the higher the moisture content of the skin stratum corneum is, namely, the better the water-retaining and moisturizing effects of the product are.

The results of the cheek skin moisture content measurements after use of the test product are shown below:

table 6 change in moisture content of stratum corneum (A.U.)

Time	Experimental group 1	Experimental group 2	Experimental group 3	Control group 1
					D0	36.72±12.62	38.20±13.54	38.35±12.97	37.23±9.17
D3	38.72±13.61	41.59±15.25	41.87±13.66	41.52±10.61
					D7	40.62±14.05	46.24±13.62	46.71±14.21	40.66±9.49
D14	40.79±13.87	42.79±14.99	45.53±12.37	43.37±9.35
					D21	42.33±15.01	45.06±15.70	45.90±13.52	--
D28	43.33±14.22	46.52±13.05	46.78±14.38	--

Test group 1: the moisture content of the skin increased by 5.45%, 10.62%, 11.08%, 15.28% and 18.00% at the return visits D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). Through analysis of variance, there was a significant difference in the moisture content of the skin at the cheek sites when back-visits were made at D3, D7, D14, D21 and D28, compared to D0 (P < 0.05).

Test group 2: the moisture content of the skin increased 8.88%, 21.06%, 12.03%, 17.97% and 21.79% at the return visits D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). Through analysis of variance, there was a significant difference in the moisture content of the skin at the cheek sites when back-visits were made at D3, D7, D14, D21 and D28, compared to D0 (P < 0.05).

Test group 3: the moisture content of the skin increased by 9.18%, 21.80%, 18.72%, 19.69% and 21.98% at the return visits D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). Through analysis of variance, there was a significant difference in the moisture content of the skin at the cheek sites when back-visits were made at D3, D7, D14, D21 and D28, compared to D0 (P < 0.05).

Control group 1: the moisture content of the skin increased by 11.53%, 9.23% and 16.50% at the return visits D3, D7 and D14, respectively, compared to the baseline value (D0). The moisture content of the skin at the cheek area was significantly different at the return visit of D3, D7, and D14 compared to D0 by analysis of variance (P < 0.05). The test results of the control group 2 were similar to the above, and the moisture content of the skin was increased, and the moisture content after 14 days was significantly different from that before the use (P < 0.05).

Through the analysis of different prescriptions, the change of the skin moisture content between each test group (1-3) and each control group (1-2) has obvious significant difference (P <0.01) when the D7 is revisited; the skin moisture content of the test group 3 is most remarkably increased, and the effect is also remarkably different from that of the test group 1 or the test group 2, (P < 0.01).

3.4.3 skin gloss analysis

The gloss of facial Skin is measured by Skin gloss meter, and a higher value indicates a more glossy Skin.

The results of the skin gloss measurements after using the test product are shown below:

TABLE 7 differential analysis of skin gloss

Test group 1: the gloss of the skin increased by 3.62%, 5.61%, 7.44%, 7.69% and 8.09% at the visits D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). The difference in formula analysis showed a significant difference in the gloss of the cheek skin at each revisit time point compared to D0 (P < 0.001).

Test group 2: the gloss of the skin increased by 5.43%, 8.28%, 10.36%, 10.85% and 11.61% at the return visits D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). There was a significant difference in gloss of cheek skin at each revisit time point compared to D0 (P <0.001) by analysis of variance.

Test group 3: the gloss of the skin increased by 6.09%, 10.00%, 12.87%, 13.68% and 14.82% at the return visits D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). The gloss of the cheek skin at each revisit time point was significantly different compared to D0 by analysis of variance (P < 0.001).

Control group 1: the gloss of the skin increased by 2.40%, 3.01% and 2.39% at the return visits D3, D7 and D14, respectively, compared to the baseline value (D0). The skin gloss at the cheek sites was significantly different at the return visit of D3 and D7 compared to D0 by analysis of variance (P < 0.01). The test results of the control group 2 were similar, the skin glossiness was increased, and there was a significant difference in the glossiness after 14 days compared to before use (P < 0.05).

The difference in formula analysis shows that the change in skin glossiness between the test group and the control group is obviously different (P <0.05) when the D3, D7 and D14 are revisited; and among them, the skin glossiness of the test group 3 is most remarkably increased, and the effect is also remarkably different from that of the test group 1 or the test group 2, (P < 0.01).

3.4.4 analysis of skin Melanin content

The content of melanin is an important factor for determining the skin color of a human body, and the higher the content of melanin, the darker the skin color. The melanin in the facial skin was measured by Mexameter MX18, and the higher the value, the higher the melanin content.

3.4.4.1 analysis of melanin content in target spot

The results of the melanin content measurements of the skin at the target pigmented spots on the face after use of the test product are shown below:

TABLE 8 differential analysis of melanin content in target stain sites

Time	Experimental group 1	Experimental group 2	Experimental group 3	Control group 1
					D0	221.38±30.21	229.19±31.38	220.56±30.67	222.32±31.61
D3	217.97±32.03	223.25±3.95	213.81±31.44	221.08±33.01
					D7	216.99±31.33	221.69±32.55	211.16±31.28	220.10±30.98
D14	213.98±31.14	217.38±31.50	205.28±30.72	218.34±30.44
					D21	213.60±30.08	216.31±31.27	202.94±32.08	--
D28	210.63±31.07	210.66±32.14	199.23±32.12	--

Test group 1: compared with the baseline value (D0), the melanin content of the skin at the target spot site was reduced by 1.54%, 1.98%, 3.34%, 3.51% and 4.86% at the visits D3, D7, D14, D21 and D28, respectively. The analysis of the formula difference shows that the skin melanin content of the target stain part at each revisit time point shows obvious significant difference (P <0.001) compared with D0.

Test group 2: the melanin content of the skin at the target stain site was reduced by 2.59%, 3.27%, 5.15%, 5.62% and 8.08% at the visits D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). The analysis of the formula difference shows that the skin melanin content of the target stain part at each revisit time point shows obvious significant difference (P <0.001) compared with D0.

Test group 3: the melanin content of the skin at the target stain site was reduced by 3.06%, 4.26%, 6.93%, 7.99% and 9.67% at the visits D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). The analysis of the formula difference shows that the skin melanin content of the target stain part at each revisit time point shows obvious significant difference (P <0.001) compared with D0.

Control group 1: the skin melanin content decreased by 0.56%, 1.00% and 1.79% at the return visits D3, D7 and D14, respectively, compared to the baseline value (D0). There was no significant difference in skin melanin content in the cheek regions compared to D0 at the return visit of D3 and D7 by analysis of variance. Similar to this, the test result of control 2 showed a decrease in melanin content, which was not significantly different from D0 after day 7 before the administration.

The analysis of the difference of the formula shows that the skin melanin content of the test group 3 is most remarkably reduced, and the effect is also remarkably different from that of the test groups 1-2 or the control groups 1-2, (P < 0.01).

3.4.4.2 analysis of melanin content in the control spot

The results of the melanin content measurements of the skin at the facial spot-free control sites after use of the test products are shown below:

TABLE 9 differential analysis of melanin content in depigmented sites

Time	Experimental group 1	Experimental group 2	Experimental group 3	Control group 1
					D0	170.98±20.88	175.84±22.69	170.45±21.97	169.98±20.08
D3	169.07±21.22	171.72±22.30	165.44±20.76	168.88±21.79
					D7	168.09±20.91	169.41±22.65	162.31±21.78	168.32±21.86
D14	167.01±21.35	166.78±21.45	158.88±20.69	167.51±21.47
					D21	166.48±21.38	165.03±21.89	156.85±21.08
D28	165.47±20.76	161.50±21.47	154.85±22.05

Test group 1: compared to the baseline value (D0), the melanin content of the skin of the spot-free control site was reduced by 1.12%, 1.69%, 2.32%, 2.63% and 3.22% at the visits D3, D7, D14, D21 and D28, respectively. The analysis of the formula difference shows that the content of the skin black pigment of the non-spot control part at each revisit time point is obviously different (P <0.001) compared with D0.

Test group 2: compared to the baseline value (D0), the melanin content of the skin of the spot-free control site was reduced by 2.34%, 3.66%, 5.15%, 6.15% and 8.16% at the visits D3, D7, D14, D21 and D28, respectively. The analysis of the formula difference shows that the content of the skin black pigment of the non-spot control part at each revisit time point is obviously different (P <0.001) compared with D0.

Test group 3: compared to the baseline value (D0), the melanin content of the skin of the spot-free control site was reduced by 2.94%, 4.79%, 6.79%, 7.98% and 9.15% at the visits D3, D7, D14, D21 and D28, respectively. The analysis of the formula difference shows that the content of the skin black pigment of the non-spot control part at each revisit time point is obviously different (P <0.001) compared with D0.

Control group: the skin melanin content decreased by 0.65%, 0.98% and 1.45% at the return visits D3, D7 and D14, respectively, compared to the baseline value (D0). There was no significant difference in skin melanin content in the cheek regions compared to D0 at the return visit of D3 and D7 by analysis of variance. The test results of control 2 were similar in that there was a decrease in melanin content, and there was no significant difference in the content after day 7 compared to D0 before the administration.

The skin melanin content of the test group 3 is most remarkably reduced, and the effect is also remarkably different from that of the test group 1 or the test group 2, (P < 0.01).

3.4.5 analysis of skin color

The facial complexion colorimetric values L, a and b are detected by a Chromameter CM-2600D instrument, the L value evaluates the brightness of the skin complexion, a and b respectively represent the degrees of reddish and yellowish skin, ITA DEG is called a hue angle and represents the fair degree of the skin, and the values are calculated through the L and b values; the larger the value of L or the smaller the values of a and b, the healthier the skin complexion. The larger the value of ITA ° obtained from L and b, the whiter the skin tone.

3.4.5.1 analysis of color intensity of target color spot

After using the test product, the facial target spot location L, b, ITA °, a value measurements are as follows:

TABLE 10 differential analysis of target stain site chromaticity

Test group 1: the target stain site L values increased by 0.65%, 0.91%, 1.12%, 1.88% and 2.38% at the visits D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). b increases by 0.94%, 1.29% and 1.93% at the return visits D3, D7 and D14, respectively, and decreases by 0.59% and 1.04% at the return visits D21 and D28, respectively. The ITA ° values rose by 4.13%, 5.93%, 6.51%, 11.39% and 14.64% at the revisits of D3, D7, D14, D21 and D28, respectively. The a values decreased by 2.10%, 2.51%, 3.21%, 5.31% and 5.61% at the visits D3, D7, D14, D21 and D28, respectively. The analysis of variance revealed that the L, b, ITA ° or a values of the target spot sites at each of the revisit time points showed significant differences (P <0.05) compared to D0.

Test group 2: the L values of the target stain sites increased by 0.91%, 1.28%, 1.60%, 2.18% and 2.71% at the visits D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). b increases by 0.88%, 0.38% and 1.70% at the return visits D3, and D14, respectively, and decreases by 0.17% and 2.20% at the return visits D21 and D28, respectively. The ITA ° values rose by 7.79%, 12.10%, 13.56%, 20.86% and 27.29% at the return visits D3, D7, D14, D21 and D28, respectively. The a values decreased by 4.15%, 4.91%, 6.06%, 9.06% and 8.48% upon revisit of D3, D7, D14, D21 and D28, respectively. The analysis of variance revealed that the L, b, ITA ° or a values of the target spot sites at each of the revisit time points showed significant differences (P <0.05) compared to D0.

Test group 3: the L values of target stain sites increased by 1.08%, 1.51%, 2.03%, 2.33% and 2.93% at the revisits of D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). b increases by 0.21%, 0.11% and 0.05% at the return visits D3, D7 and D14, respectively, and decreases by 1.48% and 2.64% at the return visits D21 and D28, respectively. The ITA ° values rose 8.29%, 13.26%, 15.04%, 24.04% and 28.83% at the revisits of D3, D7, D14, D21 and D28, respectively. The a values decreased by 5.02%, 6.11%, 7.88%, 9.85% and 10.05% upon return visits of D3, D7, D14, D21 and D28, respectively. The analysis of variance revealed that the L, b, ITA ° or a values of the target spot sites at each of the revisit time points showed significant differences (P <0.05) compared to D0.

Control group 1: the target stain site L values increased by 0.13%, 0.14%, 0.31%, 1.45% and 1.78% at the revisits of D3, D7, D14, D21 and D28, respectively, compared to the baseline value (D0). b increases by 1.05%, 1.58% and 2.21% at the return visits D3, D7 and D14, respectively, and decreases by 0.21% and 0.79% at the return visits D21 and D28, respectively. The ITA ° values rose by 1.76%, 3.00%, 3.65%, 4.23% and 7.52% at the revisits of D3, D7, D14, D21 and D28, respectively. The a values decreased by 1.07%, 1.17%, 1.46%, 2.63% and 2.73% upon revisit of D3, D7, D14, D21 and D28, respectively. The analysis of variance revealed that no significant difference was observed in the L, b, ITA ° or a values of the target spot sites at each of the revisit time points (P >0.05) compared to D0. The test results for control 2 were similar to this, and no significant difference was shown in L, b, ITA °, a at the target spot sites compared to baseline values using D3, D7, D14, D21, and D28 (P > 0.05).

The difference analysis of the formula shows that the change of the chromaticity between the test group and the control group has obvious significant difference (P <0.05) when the D3, the D7, the D14, the D21 and the D28 are visited back; among them, the skin color of test group 3 was most significantly improved, and the effect was also significantly different from that of test group 1 or test group 2 (P < 0.01).

3.4.5.2 analysis of chromaticity of unpigmented part

TABLE 11 differential analysis of chromaticity at unpigmented sites

Test group 1: compared to the baseline value (D0), the L values of the non-stained sites increased by 0.36%, 0.58%, 0.95%, 1.04% and 1.12% at the visits D3, D7, D14, D21 and D28, respectively. b increases by 2.39%, 2.74%, 3.27% and 3.33% at the return visits D3, D7 and D14, respectively, and decreases by 0.18% at the return visit D28. The ITA ° values increased by 1.65%, 3.33%, 3.39%, 5.21% and 7.52% at the return visits D3, D7, D14, D21 and D28, respectively. The a values decreased by 4.3%, 4.83%, 7.09%, 7.2% and 7.2% at the revisits of D3, D7, D14, D21 and D28, respectively. Analysis of variance revealed that the L, b, ITA ° or a ° values of the non-plaque sites at each revisit time point showed significant differences (P <0.05) compared to D0.

Test group 2: compared to the baseline value (D0), the L values of the non-stained sites increased by 0.95%, 1.31%, 1.86%, 1.98% and 2.11% at the visits D3, D7, D14, D21 and D28, respectively. b increases by 2.20%, 2.50%, 2.99% and 1.04% at the return visits D3, D7, D14 and D21, respectively, and decreases by 0.43% at the return visit D28. The ITA ° values rose by 2.19%, 3.45%, 5.00%, 6.96% and 8.53% at the revisits of D3, D7, D14, D21 and D28, respectively. The a values decreased by 6.37%, 7.90%, 11.34% and 10.44% at the revisits of D3, D7, D14, D21 and D28, respectively. The analysis of variance revealed that the L, b, ITA ° or a ° of the non-stained site at each revisit time point showed significant differences (P <0.05) compared to D0.

Test group 3: compared to the baseline value (D0), the L values of the non-stained sites increased by 1.26%, 1.8%, 2.34%, 2.61% and 2.79% at the visits D3, D7, D14, D21 and D28, respectively. b increases by 0.76%, 0.82% and 1.01% at the return visits D3, D7 and D14, respectively, and decreases by 0.70% and 0.76% at the return visits D21 and D28, respectively. The ITA ° values rose by 2.43%, 5.04%, 5.70%, 7.83% and 9.65% at the revisits of D3, D7, D14, D21 and D28, respectively. The a values decreased by 7.51%, 9.76%, 13.64%, 14.89% and 15.52% upon revisit of D3, D7, D14, D21 and D28, respectively. The analysis of variance revealed that the L, b, ITA ° or a ° of the non-stained site at each revisit time point showed significant differences (P <0.05) compared to D0.

Control group 1: compared to the baseline value (D0), the L values of the non-speckled sites decreased by 0.31%, 0.49% and 0.37% at the revisits of D3, D7 and D14, respectively. b decreases by 0.41% and 0.53% at the return visits D3 and D7, respectively, and increases by 0.60% at the return visit D14. The ITA ° values decreased by 1.00%, 1.88% and 2.20% at the revisits D3, D7 and D14, respectively. The a values increased by 1.07%, 1.34% and 0.80% at the return visits D3, D7 and D14, respectively. The analysis of variance revealed that no significant difference was observed in the L, b, ITA ° or a value of the plaque-free site at each time point of the return visit (P >0.05) compared with D0. The test results of control 2 were similar, and no significant difference was shown in L, b, ITA, a of the sites without plaques compared to the baseline values using D3, D7, D14, D21, and D28 (P > 0.05).

3.4.6 analysis of clinical Vision scores

The extent of improvement of the mottle in the subjects' faces was visually scored by qualified dermatologists before and after use of the test products.

Clinical evaluation of facial skin condition was performed by dermatologists under the criteria of SKIN AGING ATLAS 2: ASIAN TYPE (R.Bazin & F.flame, 2010 edition, MED' COM Press), the standard maps of "degree of detail of points" grade 0-7, of "Contrast of analyzed point of the face" grade 0-5 and of "Size of an analyzed point" grade 0-7 were evaluated, and the scores of such visual scores were widely used in clinical evaluation.

3.4.6.1 analysis of facial stain Density

Unilateral facial area was selected by the professional dermatologist for visual assessment. The lower the score, the lower the stain density of the face, the better the stain lightening effect of the product, and after using the test product, the density of the facial stains was unchanged at the visits D3, D7, D14, D21 and D28, compared to the score of '3.66' of the baseline value (D0), in experimental group 2, i.e. the scores mean values were all '3.66'. The analysis of the difference of the squares revealed that the stain density scores at each revisit time point did not show significant difference (P >0.05) compared to D0, and the effects of experimental group 1 and experimental group 3 were similar.

3.4.6.2 color and size analysis of facial target stain

The professional dermatologist selects a unilateral face for visual assessment. The lower the score, the lighter the target stain color indicating the face, and the better the stain lightening effect of the product. Visual evaluation is carried out on the single-sided face, the lower the score is, the smaller the target color spot of the face is, and the better the color spot fading effect of the product is: the visual scoring results of the color of the target stain on the subjects' face after using the test product are shown below:

surface 12 analysis of facial stains

Test group 1: compared to the score of '2.39' for baseline value (D0), the color score of the facial target stain rose to '2.40' at the return visit of D3 and declined to '2.35, 2.24, 2.18, 2.04' at the return visits of D7, D14, D21, and D28, respectively. In size, the score for facial target stain size was unchanged at the visit back to D3 and decreased to '3.15, 3.11, 2.93, 2.91' at visits back to D7, D14, D21 and D28, respectively, compared to the '3.17' score for baseline value (D0). The analysis of the difference of the formula shows that the target stains have significant difference in color score and size score (P <0.05) compared with D0 when the D14, D21 and D28 visit back.

Test group 2: compared to the score of '2.47' for baseline value (D0), the color score of the facial target stain rose to '2.50' at the return visit of D3 and declined to '2.41, 2.19, 2.09, and 1.88' at the return visits of D7, D14, D21, and D28, respectively. In size, the score for facial target stain size was unchanged at the visit back to D3 and decreased to '3.25, 3.13, 2.88 and 2.78' at visits back to D7, D14, D21 and D28, respectively, compared to the '3.28' score for baseline value (D0). The analysis of the difference of the formula shows that the target stains have significant difference in color score and size score (P <0.05) compared with D0 when the D14, D21 and D28 visit back.

Test group 3: compared to the score of '2.45' for baseline value (D0), the color score of the facial target stain rose to '2.46' at the return visit of D3 and declined to '2.27, 1.86, 1.74, 1.46' at the return visits of D7, D14, D21, and D28, respectively. In terms of size, the score for the size of the facial target plaques was unchanged at the return visit of D3 and decreased to '3.23, 3.02, 2.71, 2.53' at the return visits of D7, D14, D21 and D28, respectively, compared to the '3.27' score for the baseline value (D0). The analysis of the difference of the formula shows that the target stains have significant difference in color score and size score (P <0.05) compared with D0 when the D14, D21 and D28 visit back.

Control group 1: compared to the score of '2.37' for baseline value (D0), the color score of the facial target stain rose to '2.38' at the return visit of D3 and declined to '2.37, 2.35, 2.33' at the return visits of D7, D14, D21, and D28, respectively. In size, the score for the size of the facial target stain was unchanged at the visit back to D3 and decreased to '3.15, 3.14, 3.10, 3.09' at the visits back to D7, D14, D21 and D28, respectively, compared to the '3.16' score for the baseline value (D0). The analysis of the difference of the formula revealed that the target stain color score and size score were not significantly different (P >0.05) at the visits D14, D21 and D28 compared to D0. The test results for control 2 were similar, and there was no significant difference in the target plaques color score and size score at the visits D14, D21 and D28 (P >0.05) compared to D0.

The formula difference analysis shows that the change of the color of the stains between the test group and the control group is obviously different (P <0.05) when the groups are revisited by D3, D7, D14, D21 and D28; whereas the score of test group 3 was most significantly reduced, the effect was also significantly different compared to test group 1 or test group 2, (P < 0.01).

3.4.6.3 analysis of facial skin color improvement score

The degree of improvement in the mottle on the subjects' faces was visually scored by qualified dermatologists before and after use of the product, with the scoring criteria shown in table 13:

TABLE 13 reference Standard level for facial skin color improvement score

	Reference standard
		Level 0	Without any improvement
Level 1	Slight improvement
		Stage 2	Improvement in moderate degree
Grade 3	Obviously improve

The visual scoring results of the degree of improvement in facial skin color of the subjects after use of the test products are shown below:

TABLE 14 analysis of facial skin tone improvement score

Time	Experimental group 1	Experimental group 2	Experimental group 3	Control group 1
					D0		--
D3	0.15±0.41	0.16±0.37	0.24±0.39	0.13±0.40
					D7	0.30±0.38	0.34±0.48	0.49±0.42	0.21±0.42
D14	0.48±0.39	0.63±0.49	0.91±0.38	0.29±0.38
					D21	0.50±0.42	0.66±0.48	1.02±0.44	0.32±0.37
D28	0.60±0.43	0.81±0.40	1.35±0.41	0.36±0.40

Test group 1: the degree of improvement in skin color was scored at 0.15, 0.30, 0.48, 0.50, 0.60' at the time of return visits D3, D7, D14, D21 and D28. Through analysis of different prescriptions, the skin color improvement degree scores showed significant differences (P <0.05) compared with D3 at the visits D7, D14, D21 and D28.

Test group 2: the degree of improvement in skin color was scored as '0.16, 0.34, 0.63, 0.66 and 0.81' at the time of return visits D3, D7, D14, D21 and D28. Through analysis of different prescriptions, the skin color improvement degree scores showed significant differences (P <0.05) compared with D3 at the visits D7, D14, D21 and D28.

Test group 3: the degree of improvement in skin color scored 0.24, 0.49, 0.91, 1.02, 1.35' at the time of return visits D3, D7, D14, D21 and D28. Through analysis of different prescriptions, the skin color improvement degree scores showed significant differences (P <0.05) compared with D3 at the visits D7, D14, D21 and D28.

Control group 1: the degree of improvement in skin color was scored at 0.13, 0.21, 0.29, 0.32, 0.36' at the time of return visits D3, D7, D14, D21 and D28. The analysis of the difference of the formula shows that the scores of the skin color improvement degree do not show significant difference (P >0.05) compared with D3 when the D7, D14, D21 and D28 visit back. The score of control 2 was similar to that, and the analysis of the difference between the formulas revealed that the skin color improvement score did not show significant difference (P >0.05) at the visits D7, D14, D21 and D28 compared to D3.

The formula difference analysis shows that the change of the color of the stains between the test group and the control group is obviously different (P <0.05) when the test group and the control group are revisited by D7, D14, D21 and D28; whereas the score reduction was most significant in test group 3, the effect was also significantly different compared to test group 1 or test group 2, (P < 0.01).

3.4.7 subject self-assessment questionnaire analysis

Each subject completed the self-assessment questionnaire after product use at the time of return visits D7, D14 and D28. The test products were evaluated by the subjects according to subjective feeling after using the test products. The score is performed by the subject in conjunction with a self-perception reference scoring criteria. The result score was assigned a score of 0 to 9 (where: 0-very unsatisfactory results of use of the test product and 9-very satisfactory results of use of the test product). According to the evaluation criteria, each subject evaluated the texture and other characteristics and efficacy of the test product, including product moisturization, improvement in skin texture, improvement in skin radiance, lightening mottle, and lightening skin tone, after using the test product.

After using the product of example 2 (at the return visit of D7), more than 84% of the subjects had a high degree of satisfaction with the characteristics of the product, such as smell, texture and texture, and more than 93% of the subjects showed satisfaction with the absorption and ease of use of the product. Not less than 78% of the subjects are satisfied with the effects of nourishing skin, smoothing skin texture and the like of the product; at least 75% of the subjects considered the product to be able to even the skin and make the skin white and shiny; over 62% of subjects believe that the product can lighten the color of the stain, reduce the number of stains, and reduce problems with skin blemishes, and the like.

After using the product of example 2 (at the return visit of D28), more than 84% of the subjects showed satisfactory results in terms of skin nourishment, fine skin texture, etc. of the product; at least 84 percent of subjects think that the product can evenly tone the skin and make the skin white and glossy; over 78% of the subjects considered the product to lighten the color of the stain, reduce the number of stains, and reduce the problems of skin blemishes, and the like. Over 96% of the subjects indicated satisfaction with the overall efficacy of the product; at least 93% of the subjects are willing to purchase the test product regardless of the price of the product.

This effect was not obtained with the product of example 1 or example 3, and the satisfaction was poor, whereas the subjects of the control group who had undergone only daily care showed no significant improvement in skin color.

3.5 conclusion

The clinical whitening efficacy test of the whitening mask & moisturizing cream & sunscreen cream provided by the embodiment 2 of the invention by a test subject for 28 days of continuous use shows that:

1. after the test product is used, the moisture content of the skin stratum corneum of the subject has a remarkable trend (P <0.05), which shows that the test product has the efficacies of moisturizing and nourishing the skin.

2. There was a tendency for the skin gloss of the subjects to increase significantly after the test product was used (P < 0.01); compared with a control group, the whitening mask of the test group has better effect of improving the skin luster.

3. After the test product is used, the skin melanin content of a subject has an obvious reduction trend (P <0.001), which shows that the whitening facial mask of the test group has the effects of whitening and brightening the skin.

4. After the test product is used, the skin color L value and the ITA DEG value of the subject have obvious rising trends (P <0.001), b value and a value have certain descending trends; compared with a control group, the whitening mask of the test group has better effects of improving skin chromaticity and promoting skin whiteness.

5. After the test product is used, the visual scores of the color and the size of the skin color spots of the subjects have a remarkable descending trend (P <0.05), and the scores of the skin color improvement degrees have a remarkable ascending trend (P <0.05), which shows that the whitening facial mask of the test group has good effects of lightening color spots and improving skin color.

6. According to the self-evaluation result of the testee, the whitening mask has certain effects of moistening the skin, improving the texture, brightening the skin color, whitening the skin and the like.

7. The tested product has better safety.

The foregoing is only a preferred embodiment of the present invention, and it should be noted that it is obvious to those skilled in the art that various modifications and improvements can be made without departing from the principle of the present invention, and these modifications and improvements should also be considered as the protection scope of the present invention.

Claims

1. A whitening composition characterized by comprising, in a major amount,

the composition comprises the following components in parts by mass:

3 parts of 1, 3-butanediol,

0.03 portion of hyaluronic acid,

0.05 part of allantoin,

Ascorbic acid glucoside 0.3 part,

0.03 part of D-panthenol,

0.03 portion of dipotassium glycyrrhizinate,

0.5 part of nicotinamide,

1 part of oat beta glucan,

0.3 portion of trehalose,

0.5 portion of betaine,

0.2 portion of p-hydroxyacetophenone,

0.2 portion of 1, 2-hexanediol,

1 part of glycerol,

261 portions of glycerol polyether,

1.101 parts of extract composition;

or the composition comprises the following components in parts by mass:

5 parts of 1, 3-butanediol,

0.06 portion of hyaluronic acid,

0.05 part of allantoin,

Ascorbic acid glucoside 0.5 part,

0.06 part of D-panthenol,

0.03 portion of dipotassium glycyrrhizinate,

0.5 part of nicotinamide,

1.5 parts of oat beta glucan,

1 part of trehalose,

1 part of betaine,

0.3 portion of p-hydroxyacetophenone,

0.3 part of 1, 2-hexanediol,

2 parts of glycerol,

Glycerol polyether-262 parts,

2.502 parts of extract composition;

or the composition comprises the following components in parts by mass:

7 parts of 1, 3-butanediol,

0.1 part of hyaluronic acid,

0.05 part of allantoin,

Ascorbic acid glucoside 1 part,

0.1 part of D-panthenol,

0.03 portion of dipotassium glycyrrhizinate,

1 part of nicotinamide,

2 parts of oat beta glucan,

1.5 parts of trehalose,

1.5 portions of betaine,

0.4 portion of p-hydroxyacetophenone,

0.4 part of 1, 2-hexanediol,

3 parts of glycerol,

Glycerine polyether-263 weight portions,

4.503 parts of an extract composition;

the extract composition consists of the following components: mushroom extract, safflower extract, centella asiatica extract, polygonum cuspidatum root extract, scutellaria baicalensis root extract, tea leaf extract, chamomile flower extract, rosemary leaf extract, glycyrrhiza glabra root extract, artemisia capillaris flower extract, mulberry root extract and jujube fruit extract;

in the extract composition, the mass ratio of each component is as follows: mushroom extract, safflower extract, centella asiatica extract, polygonum cuspidatum root extract, scutellaria baicalensis root extract, tea leaf extract, glycyrrhiza glabra root extract, chamomile flower extract, rosemary leaf extract, artemisia capillaris flower extract, mulberry root extract and jujube fruit extract = (0.5-1.5): (0.001-0.003): (0.05-0.3): (0.05-0.3): (0.05-0.3): (0.05-0.2): (0.1-1): (0.1-0.3): (0.1-0.3): (0.03-0.2): (0.02-0.3): (0.05-0.5).

2. Use of the whitening composition of claim 1 in the preparation of cosmetics.

3. A cosmetic comprising the whitening composition of claim 1.

4. The cosmetic according to claim 3, wherein the whitening composition of claim 1 is 9.241%, 16.802% or 25.583% by mass.

5. The cosmetic according to claim 4, further comprising: water, thickening agent, pH regulator, solubilizer, preservative, buffering agent, chelating agent and essence;

the thickening agent is xanthan gum and carbomer U-20;

the pH regulator is arginine;

the solubilizer is PEG-60 hydrogenated castor oil;

the preservative is methyl paraben;

the buffer is sodium citrate and citric acid;

the chelating agent is disodium EDTA.

6. The cosmetic according to claim 4 or 5,

the composite material comprises the following components in percentage by mass:

3 percent of 1, 3-butanediol,

0.03 percent of hyaluronic acid,

0.05 percent of allantoin,

0.3 percent of ascorbyl glucoside,

0.03 percent of D-panthenol,

0.03 percent of dipotassium glycyrrhizinate,

0.5 percent of nicotinamide,

1 percent of oat beta glucan,

0.3 percent of trehalose,

0.5 percent of betaine,

0.2 percent of p-hydroxyacetophenone,

0.2 percent of 1, 2-hexanediol,

1 percent of glycerin,

261 percent of glycerol polyether,

1.101 percent of extract composition,

0.1 percent of xanthan gum,

200.1 percent of carbomer U,

0.05 percent of methylparaben,

0.02 percent of disodium ethylene diamine tetraacetate,

0.02 percent of citric acid,

0.03 percent of sodium citrate,

0.12 percent of arginine,

0.006 percent of essence,

0.06 percent of PEG-60 hydrogenated castor oil,

The balance of water;

or the composition comprises the following components in percentage by mass:

5 percent of 1, 3-butanediol,

0.06 percent of hyaluronic acid,

0.05 percent of allantoin,

0.5 percent of ascorbyl glucoside,

0.06 percent of D-panthenol,

0.03 percent of dipotassium glycyrrhizinate,

0.5 percent of nicotinamide,

1.5 percent of oat beta glucan,

1 percent of trehalose,

1 percent of betaine,

0.3 percent of p-hydroxyacetophenone,

0.3 percent of 1, 2-hexanediol,

2 percent of glycerin,

Glycerin polyether-262%,

2.502 percent of extract composition,

0.1 percent of xanthan gum,

200.1 percent of carbomer U,

0.05 percent of methylparaben,

0.02 percent of disodium ethylene diamine tetraacetate,

0.02 percent of citric acid,

0.03 percent of sodium citrate,

0.12 percent of arginine,

0.006 percent of essence,

0.06 percent of PEG-60 hydrogenated castor oil,

The balance of water;

or the composition comprises the following components in percentage by mass:

7 percent of 1, 3-butanediol,

0.1 percent of hyaluronic acid,

0.05 percent of allantoin,

1% of ascorbyl glucoside,

0.1 percent of D-panthenol,

0.03 percent of dipotassium glycyrrhizinate,

1% of nicotinamide,

2 percent of oat beta glucan,

1.5 percent of trehalose,

1.5 percent of betaine,

0.4 percent of p-hydroxyacetophenone,

0.4 percent of 1, 2-hexanediol,

3 percent of glycerin,

Glycerin polyether-263%,

4.503 percent of extract composition,

0.1 percent of xanthan gum,

200.1 percent of carbomer U,

0.05 percent of methylparaben,

0.02 percent of disodium ethylene diamine tetraacetate,

0.02 percent of citric acid,

0.03 percent of sodium citrate,

0.12 percent of arginine,

0.006 percent of essence,

0.06 percent of PEG-60 hydrogenated castor oil,

The balance of water.

7. The cosmetic according to any one of claims 4 to 6, which is a mask.